Thought-powered robotic hand unveiled: LifeHand, a European project to develop an implanted, electrode-controlled prosthetic hand just showed off its first human subject, who used the device for an entire month. Unlike with many other prostheses, Pierpaolo Petruzziello was able to use pure thought to move the fingers of the hand and perform fairly advanced tasks.
Sales of Boston Scientific Corp.‘s Taxus drug-eluting stent have been declining since 2006, according to restated earnings reports from Angiotech Pharmaceuticals Inc., which makes paclitaxel, the drug used in the stent’s coating.
The Vancouver-based pharmaceutical company’s drug is designed to reduce restenosis, or the re-narrowing of blood vessels after stents are implanted. Angiotech reaps just under 7 percent of the net sales of Taxus stents worldwide, in royalties for BSX’s use of its product.
Hard on the heels of its Beantown-based rival, Boston Scientific, Abbott announced CE Marks for its Xience Prime and Xience V drug-eluting stents, clearing the way for their use in treating diabetes in the European Union.
The news follows BSX’s announcement of CE Marking for its Promus Element stent.
Chicago-based Abbott said EU regulators clearing its devices for use in treating coronary artery disease in difficult-to-treat diabetic patients, who tend to have smaller blood vessels and longer lesions.
Boston Scientific said it will immediately begin to market its Promus Element drug-eluting stent in the European Union, now that it’s won CE Mark approval for the device.
Cordis Corp. and pharma giant Wyeth asked a Minnesota judge to dismiss a counter-suit filed by Boston Scientific Corp. over a patent for stent coatings.
The Johnson & Johnson subsidiary and Wyeth sued BSX and Abbott Sept. 22 in the U.S. District Court for New Jersey, alleging infringement of a coatings patent for coronary stents with Abbott’s Xience V stent (which BoSci sells as the Promus).
Campbell Rogers, the chief scientific officer for Johnson & Johnson subsidiary Cordis Corp., knows interventional cardiology from both sides of the clinical trial.
As the former director Brigham & Women’s Hospital’s catheterization lab and principal investigator of the Brigham’s interventional vascular biology laboratory, Rogers led multi-center device and pharmacologic trials before joining Cordis in July 2006.
There he finds himself on the other side of the process as head of Cordis’ research and development team — a role the company created for him.
It looks as though Boston Scientific Corp. might have left its heart (and some business) in San Francisco.
To say its been a rough week at the annual Transcatheter Cardiovascular Therapeutics meeting would be a grotesque understatement, as the Natick-based coronary stent colossus suffered a series of high-profile setbacks at the annual meeting of thousands of cardiologists from around the world.
A small version of Cordis Corp.‘s Cypher drug-eluting stent won approval from the Food & Drug Administration for treating blockages in small blood vessels.
The Bridgewater, N.J.-based Johnson & Johnson subsidiary said the federal watchdog’s approval of its 2.25mm Cypher sirolimus-eluting coronary stent was based on a quartet of studies comparing it to bare-metal stents.